Fractionated radiation alters oncomir and tumor suppressor miRNAs in human prostate cancer cells

Radiation Research

Volumn 178, Issue 3, 2012, Pages 105-117

  John Aryankalayil, Molykutty ^a   Palayoor, Sanjeewani T ^a   Makinde, Adeola Y ^a   Cerna, David ^a   Simone II, Charles B ^a   Falduto, Michael T ^b   Magnuson, Scott R ^b   Coleman, C Norman ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GenUs BioSystems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MESSENGER RNA; MICRORNA; MICRORNA 101; MICRORNA 130; MICRORNA 146A; MICRORNA 15; MICRORNA 154; MICRORNA 17; MICRORNA 17 92; MICRORNA 193; MICRORNA 19A; MICRORNA 22; MICRORNA 221; MICRORNA 23; MICRORNA 27; MICRORNA 28; MICRORNA 29; MICRORNA 30; MICRORNA 331; MICRORNA 34A; MICRORNA 361; MICRORNA 47; MICRORNA 48; MICRORNA 6; MICRORNA 8; MICRORNA 99; PROTEIN LET 7; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN LNCAP; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INNATE IMMUNITY; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

CELL LINE, TUMOR; DOSE FRACTIONATION; EPITHELIAL CELLS; HOT TEMPERATURE; HUMANS; IMMUNITY, INNATE; MALE; MICRORNAS; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; REPRODUCIBILITY OF RESULTS; TRANSCRIPTOME;

EID: 84866341565     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2703.1     Document Type: Article

References (58)

1. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006; 20(5):515-24. (Pubitemid 43345317)
2. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433(7027):769-73. (Pubitemid 40292988)
3. Cha HJ, Shin S, Yoo H, Lee EM, Bae S, Yang KH, et al. Identification of ionizing radiation-responsive microRNAs in the IM9 human B lymphoblastic cell line. Int J Oncol 2009; 34(6): 1661-8.
4. Guo Y, Li S, Qu J, Wang S, Dang Y, Fan J, et al. MiR-34a inhibits lymphatic metastasis potential of mouse hepatoma cells. Mol Cell Biochem 2011.
5. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67(16): 7713-22. (Pubitemid 47281364)
6. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120(5):635-47. (Pubitemid 40343076)
7. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther 2008; 7(8): 1288-96.
8. Wang Y, Scheiber MN, Neumann C, Calin GA, Zhou D. MicroRNA Regulation of ionizing radiation-induced premature senescence. Int J Radiat Oncol Biol Phys 2010.
9. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101(9):2999-3004. (Pubitemid 38327724)
10. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007; 7(11):819-22. (Pubitemid 350006254)
11. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435(7043):828-33. (Pubitemid 40839734)
12. Kato M, Paranjape T, Muller RU, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, et al. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene 2009; 28(25):2419-24.
13. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65(21):9628-32. (Pubitemid 41541436)
14. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435(7043):834-8. (Pubitemid 40839735)
15. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009; 23(24):2839-49.
16. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008; 377(1):114-9.
17. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64(11):3753-6. (Pubitemid 38697282)
18. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6(11):857-66. (Pubitemid 44629897)
19. Osada H, Takahashi T. let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci 2011; 102(1): 9-17.
20. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103(7): 2257-61. (Pubitemid 43271657)
21. Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, et al. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One 2008; 3(4):e1908.
22. Gandellini P, Profumo V, Folini M, Zaffaroni N. MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin Ther Targets 2011; 15(3):265-79.
23. Wu W. MicroRNAs Patents: The road from bench to bedsides for cancer treatment. Recent Pat DNA Gene Seq 2011.
24. Arora H, Qureshi R, Jin S, Park AK, Park WY. miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFkappaB1. Exp Mol Med 2011; 43(5):298-304.
25. Chaudhry MA, Kreger B, Omaruddin RA. Transcriptional modulation of micro-RNA in human cells differing in radiation sensitivity. Int J Radiat Biol 2010; 86(7):569-83.
26. Simone NL, Soule BP, Ly D, Saleh AD, Savage JE, Degraff W, et al. Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One 2009; 4(7):e6377.
27. Wagner-Ecker M, Schwager C, Wirkner U, Abdollahi A, Huber PE. MicroRNA expression after ionizing radiation in human endothelial cells. Radiat Oncol 2010; 5:25.
28. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67(23):11111-6. (Pubitemid 350248533)
29. Jiang P, Rao EY, Meng N, Zhao Y, Wang JJ. MicroRNA-17-92 significantly enhances radioresistance in human mantle cell lymphoma cells. Radiat Oncol 2010; 5:100.
30. John-Aryankalayil M, Palayoor ST, Cerna D, Simone CB, 2nd, Falduto MT, Magnuson SR, et al. Fractionated radiation therapy can induce a molecular profile for therapeutic targeting. Radiat Res 2010; 174(4):446-58.
31. Albright N. Computer programs for the analysis of cellular survival data. Radiat Res 1987; 112(2):331-40. (Pubitemid 18015902)
32. John-Aryankalayil M, Palayoor ST, Cerna D, Falduto MT, Magnuson SR, Coleman CN. NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Mol Cancer Ther 2009; 8(1):261-73.
33. Shin S, Cha HJ, Lee EM, Jung JH, Lee SJ, Park IC, et al. MicroRNAs are significantly influenced by p53 and radiation in HCT116 human colon carcinoma cells. Int J Oncol 2009; 34(6): 1645-52.
34. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447(7148):1130-4. (Pubitemid 47014436)
35. Josson S, Sung SY, Lao K, Chung LW, Johnstone PA. Radiation modulation of microRNA in prostate cancer cell lines. Prostate 2008; 68(15):1599-606.
36. Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Res 2006; 66(22):10843-8. (Pubitemid 44876980)
37. Niemoeller OM, Niyazi M, Corradini S, Zehentmayr F, Li M, Lauber K, et al. MicroRNA expression profiles in human cancer cells after ionizing radiation. Radiat Oncol 2011; 6:29.
38. Shin S, Cha HJ, Lee EM, Lee SJ, Seo SK, Jin HO, et al. Alteration of miRNA profiles by ionizing radiation in A549 human non-small cell lung cancer cells. Int J Oncol 2009; 35(1):81-6.
39. Templin T, Paul S, Amundson SA, Young EF, Barker CA, Wolden SL, et al. Radiation-induced micro-RNA expression changes in peripheral blood cells of radiotherapy patients. Int J Radiat Oncol Biol Phys 2011; 80(2):549-57.
40. Vincenti S, Brillante N, Lanza V, Bozzoni I, Presutti C, Chiani F, et al. HUVEC Respond to radiation by inducing the expression of pro-angiogenic microRNAs. Radiat Res 2011; 175(5):535-46.
41. Hermeking H. p53 enters the microRNA world. Cancer Cell 2007; 12(5):414-8. (Pubitemid 350046413)
42. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17(2):193-9.
43. Morgan WF. Communicating non-targeted effects of ionizing radiation to achieve adaptive homeostasis in tissues. Curr Mol Pharmacol 2010.
44. Chen X, Yan J, Chen T. Expression level of miR-34a rather than P53 gene status correlates with mutability in related human lymphoblast cell lines. Mol Carcinog 2011.
45. Navarro F, Gutman D, Meire E, Caceres M, Rigoutsos I, Bentwich Z, et al. miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53. Blood 2009; 114(10):2181-92.
46. Luan S, Sun L, Huang F. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251. Arch Med Res 2010; 41(2):67-74.
47. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, etal. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010; 70(14): 5923-30.
48. Wang WL, Chatterjee N, Chittur SV, Welsh J, Tenniswood MP. Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer 2011; 10:58.
49. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008; 132(5):875-86. (Pubitemid 351312807)
50. Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, et al. Genetic dissection of the miR-17;92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 2009; 23(24): 2806-11.
51. Dong Q, Meng P, Wang T, Qin W, Wang F, Yuan J, et al. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One 2010; 5(4):e10147.
52. Li Y, Vandenboom TG, 2nd, Wang Z, Kong D, Ali S, Philip PA, et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 2010; 70(4):1486-95.
53. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008; 14(3):417-24. (Pubitemid 351397806)
54. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, et al. MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging 2009; 1(4):402-11.
55. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaBdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103(33):12481-6. (Pubitemid 44267285)
56. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136(2):215-33.
57. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, et al. Kauppinen S. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452(7189):896-9. (Pubitemid 351550859)
58. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010; 18(1):181-7.